Cyclin-dependent kinase 1 (CDK1)

Where the papers sit

12 papers from the last 6 months study Cyclin-dependent kinase 1 (CDK1) directly · updated from PubMed 10 Oct 2026

• CDK1-Linked Cell-Cycle Pathology

  CDK1 is repeatedly linked to abnormal proliferation, G2/M arrest, invasion, and tissue injury across cancers and nonmalignant disease. Preclinical interventions suppress CDK1 directly or through regulators such as Wee1, with apoptosis and reduced colony formation as recurring endpoints. Trichodermin, H101, and astragaloside-brucea javanica nanoemulsion exemplify therapeutic approaches, while elafibranor and TET2 studies connect CDK1 to vascular and renal injury. The breadth of models supports CDK1 as a progression node, but disease-specific mechanisms and clinical translation remain unresolved.

  6 papers · 50%

• CDK1-Cyclin B1 Therapeutics

  CDK1/Cyclin B1 is being framed as a cancer vulnerability connected to mitochondrial remodeling and cell-cycle control. In cervical cancer, Drp1-dependent mitochondrial fission links CDK1/Cyclin B1 signaling to tumor-cell viability. Selective PKMYT1/WEE1 dual inhibitors represent a parallel effort to manipulate the CDK1 activation network pharmacologically. Multi-omics and network toxicology broaden target discovery, but the evidence remains largely mechanistic and preclinical.

  4 papers · 33.3%

• Computational Kinase Inhibitor Design

  Structure-guided modeling is being used to optimize selective CDK inhibitors, especially pyrazolo-pyrimidine compounds aimed at CDK1. 3D-QSAR, docking, molecular dynamics, and calculated binding energies are used to rank candidates and explain kinase selectivity. Mechanistic pharmacokinetic modeling extends the same computational strategy to CDK2 inhibitors. The main open step is biochemical and cellular validation beyond predicted affinity and conformational stability.

  2 papers · 16.7%